From: Recent progress in West Nile virus diagnosis and vaccination
Name | Viral antigen(s) | State of development | Reference |
---|---|---|---|
West Nile-Innovator (Pfizer) RecombiTek (Merial) | Whole virus WNV prM-E in canarypox virus | Commercialized for horses Commercialized for horses | [63] |
West Nile-Innovator DNA | Plasmid DNA prM/E | Licensed for horses | [23] |
PreveNile (Intervet) | WNV prM-E in yellow fever backbone | Commercialized for horses (recalled in 2010) | Â |
Vetera West Nile vaccine (Boehringer Ingelheim) | Killed virus | Commercialized for horses | Â |
ChimeriVax (Sanofi) | Yellow fever PrM-E substituted by WNV prM-E | Phase II human clinical trial | |
WN-DEN4 | WNV prM-E in dengue-4 backbone | Phase II human clinical trial | [72] |
VRC303 (NIAID/Vical) | Plasmid encoding WNV prM and E | Phase I human clinical trial | [41] |
STF2Δ.EIII | S. typhimurium flagellin fused to E domain III | Evaluated in mice | [55] |
rWNV-ET | Truncated protein E | Evaluated in mice and horses | |
SRIP | prM-E VLPs | Evaluated in mice and horses | [12] |
RepliVAX WN | Single-cycle West Nile virus | Evaluated in mice [118], hamsters [119], non-human primates [120] | Â |
 | Plasmid encoding E domain III fused to P28 | Evaluated in mice | [22] |
DIII-C-AP205 | E domain III coupled to bacteriophage AP205 | Evaluated in mice | [87] |
FLU-NA-DIII | E domain III inserted into NA of influenza | Evaluated in mice | [54] |
CAdVax-WNVII | C, preM, E and NS1 expressed in adenovirus | Evaluated in mice | [81] |